China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

The breast cancer drug Enhertu will be added to China’s national health insurance scheme beginning in the new year — despite ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

Alteogen公司近日宣布，其已与第一三共（Daiichi Sankyo）达成独家许可协议。第一三共将获得在全球范围内使用ALT-B4 ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...

Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...

The latest health news includes China allowing foreign-owned hospitals in major cities, and the inclusion of AstraZeneca's ...